CLINICAL TRIALS
Active clinical trials and verified researcher listings for Lung Cancer (NSCLC), simplified into plain English.
ABOUT LUNG CANCER (NSCLC)
Lung cancer, also called lung carcinoma, is a malignant tumor that originates in the tissues of the lungs. Lung cancer is caused by genetic damage to the DNA of cells in the airways, often caused by cigarette smoking or inhaling damaging chemicals. Damaged airway cells gain the ability to multiply unchecked, causing the growth of a tumor. Without treatment, tumors spread throughout the lung, damaging lung function. Eventually lung tumors metastasize, spreading to other parts of the body.
Source: Wikipedia. For educational use only — not medical advice.
ACTIVELY RECRUITING TRIALS
COMMON QUESTIONS
Are there clinical trials currently recruiting for Lung Cancer (NSCLC)?
Yes. This page displays actively recruiting Lung Cancer (NSCLC) clinical trials sourced in real time from ClinicalTrials.gov. Use the filters to narrow by phase, status, and location.
How do I join a clinical trial for Lung Cancer (NSCLC)?
Browse the trials listed above, review the eligibility criteria for each study, and submit a contact request directly to the research team. You can also speak to your physician about a referral.
Are Lung Cancer (NSCLC) clinical trials free to participate in?
Most clinical trials cover the cost of the investigational treatment and all study-related visits. Some studies also offer compensation for time and travel. Always confirm costs and insurance coverage with the trial coordinator before enrolling.
What eligibility requirements apply to Lung Cancer (NSCLC) trials?
Requirements vary by study. Common criteria include a confirmed Lung Cancer (NSCLC) diagnosis, age range, prior treatments, and general health status. Each trial listing shows its specific inclusion and exclusion criteria.
What phases of Lung Cancer (NSCLC) trials are available?
Lung Cancer (NSCLC) trials span Phase I (safety testing), Phase II (effectiveness), Phase III (comparison to standard care), and Phase IV (post-approval monitoring). Phase II and III trials are most commonly open to new participants.